MCP-1 and IL-8 as Pain Biomarkers in Fibromyalgia: A Pilot Study

Pain Medicine

Volumn 12, Issue 8, 2011, Pages 1154-1161

  Ang, Dennis C ^a   Moore, Michele N ^a   Hilligoss, Janna ^a   Tabbey, Rebeka ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Biomarkers; Chemokines; Chronic Pain; Fibromyalgia; IL 8; MCP 1

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; BRIEF PAIN INVENTORY; CLINICAL ARTICLE; DEPRESSION; DISEASE SEVERITY; FEMALE; FIBROMYALGIA; HUMAN; PAIN ASSESSMENT; PILOT STUDY; PROTEIN BLOOD LEVEL;

EID: 80051678516     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2011.01179.x     Document Type: Article

References (49)

1. Lawrence RC, Felson DT, Helmick CG, etal. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58(1):26-35.
2. Wolfe F, Clauw DJ, Fitzcharles MA, etal. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62(5):600-10.
3. Wolfe F, Smythe HA, Yunus MB, etal. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33(2):160-72.
4. Gracely RH, Grant MA, Giesecke T. Evoked pain measures in fibromyalgia. Best Pract Res Clin Rheumatol 2003;17(4):593-609.
5. McLean SA, Williams DA, Stein PK, etal. Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. Neuropsychopharmacology 2006;31(12):2776-82.
6. Riedel W, Schlapp U, Leck S, Netter P, Neeck G. Blunted ACTH and cortisol responses to systemic injection of corticotropin-releasing hormone (CRH) in fibromyalgia: Role of somatostatin and CRH-binding protein. Ann N Y Acad Sci 2002;966:483-90.
7. Blanco I, Beritze N, Arguelles M, etal. Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients. Clin Rheumatol 2010;29(12):1403-12.
8. Enestrom S, Bengtsson A, Frodin T. Dermal IgG deposits and increase of mast cells in patients with fibromyalgia-relevant findings or epiphenomena? Scand J Rheumatol 1997;26(4):308-13.
9. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: New features for diagnosis. Pain 1988;32(1):21-6.
10. Russell IJ, Orr MD, Littman B, etal. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994;37(11):1593-601.
11. Kulka M, Sheen CH, Tancowny BP, Grammer LC, Schleimer RP. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 2008;123(3):398-410.
12. Wallace DJ, Linker-Israeli M, Hallegua D, etal. Cytokines play an aetiopathogenetic role in fibromyalgia: A hypothesis and pilot study. Rheumatology (Oxford) 2001;40(7):743-9.
13. Gur A, Karakoc M, Nas K, etal. Cytokines and depression in cases with fibromyalgia. J Rheumatol 2002;29(2):358-61.
14. Zhang Z, Cherryholmes G, Mao A, etal. High plasma levels of MCP-1 and eotaxin provide evidence for an immunological basis of fibromyalgia. Exp Biol Med (Maywood) 2008;233(9):1171-80.
15. Bazzichi L, Rossi A, Massimetti G, etal. Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clin Exp Rheumatol 2007;25(2):225-30.
16. Abbadie C, Lindia JA, Cumiskey AM, etal. Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci U S A 2003;100(13):7947-52.
17. Jeon SM, Lee KM, Cho HJ. Expression of monocyte chemoattractant protein-1 in rat dorsal root ganglia and spinal cord in experimental models of neuropathic pain. Brain Res 2009;1251:103-11.
18. Di FM, Iannuccelli C, Valesini G. Neuroendocrine immunology of fibromyalgia. Ann N Y Acad Sci 2010;1193:84-90.
19. Ang DC, Chakr R, Mazzuca S, etal. Cognitive-behavioral therapy attenuates nociceptive responding in patients with fibromyalgia: A pilot study. Arthritis Care Res (Hoboken) 2010;62(5):618-23.
20. Von KM, Jensen MP, Karoly P. Assessing global pain severity by self-report in clinical and health services research. Spine 2000;25(24):3140-51.
21. Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain 2004;5(2):133-7.
22. Arnold LM, Lu Y, Crofford LJ, etal. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50(9):2974-84.
23. Corson K, Gerrity MS, Dobscha SK. Screening for depression and suicidality in a VA primary care setting: 2 items are better than 1 item. Am J Manag Care 2004;10(11 Pt 2):839-45.
24. Kroenke K, Strine TW, Spitzer RL, etal. The PHQ-8 as a measure of current depression in the general population. J Affect Disord 2009;114(1-3):163-73.
25. Kroenke K, Spitzer RL, Williams JB, Lowe B. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: A systematic review. Gen Hosp Psychiatry 2010;32(4):345-59.
26. Pressler SJ, Subramanian U, Perkins SM, etal. Measuring depressive symptoms in heart failure: Validity and reliability of the Patient Health Questionnaire-8. Am J Crit Care 2011;20(2):146-52.
27. Smith MV, Gotman N, Lin H, Yonkers KA. Do the PHQ-8 and the PHQ-2 accurately screen for depressive disorders in a sample of pregnant women? Gen Hosp Psychiatry 2010;32(5):544-8.
28. Bennett R. The Fibromyalgia Impact Questionnaire (FIQ): A review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol 2005;23(5 suppl 39):S154-62.
29. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: Development and validation. J Rheumatol 1991;18(5):728-33.
30. Wallace DJ, Margolin K, Waller P. Fibromyalgia and interleukin-2 therapy for malignancy. Ann Intern Med 1988;108(6):909.
31. Wallace DJ. Is there a role for cytokine based therapies in fibromyalgia. Curr Pharm Des 2006;12(1):17-22.
32. Gur A, Oktayoglu P. Status of immune mediators in fibromyalgia. Curr Pain Headache Rep 2008;12(3):175-81.
33. Uceyler N, Valenza R, Stock M, etal. Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain. Arthritis Rheum 2006;54(8):2656-64.
34. Wang H, Buchner M, Moser MT, Daniel V, Schiltenwolf M. The role of IL-8 in patients with fibromyalgia: A prospective longitudinal study of 6 months. Clin J Pain 2009;25(1):1-4.
35. Cao J, Cetrulo CL, Theoharides TC. Corticotropin-releasing hormone induces vascular endothelial growth factor release from human mast cells via the cAMP/protein kinase A/p38 mitogen-activated protein kinase pathway. Mol Pharmacol 2006;69(3):998-1006.
36. Theoharides TC, Donelan JM, Papadopoulou N, etal. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci 2004;25(11):563-8.
37. Cairns JA, Walls AF. Mast cell tryptase is a mitogen for epithelial cells. Stimulation of IL-8 production and intercellular adhesion molecule-1 expression. J Immunol 1996;156(1):275-83.
38. Fischer M, Harvima IT, Carvalho RF, etal. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest 2006;116(10):2748-56.
39. Gurish MF, Boyce JA. Mast cells: Ontogeny, homing, and recruitment of a unique innate effector cell. J Allergy Clin Immunol 2006;117(6):1285-91.
40. Kimura Y, Pawankar R, Aoki M, Niimi Y, Kawana S. Mast cells and T cells in Kimura's disease express increased levels of interleukin-4, interleukin-5, eotaxin and RANTES. Clin Exp Allergy 2002;32(12):1787-93.
41. Moller A, Lippert U, Lessmann D, etal. Human mast cells produce IL-8. J Immunol 1993;151(6):3261-6.
42. Skofitsch G, Savitt JM, Jacobowitz DM. Suggestive evidence for a functional unit between mast cells and substance P fibers in the rat diaphragm and mesentery. Histochemistry 1985;82(1):5-8.
43. Sugiura H, Maeda T, Uehara M. Mast cell invasion of peripheral nerve in skin lesions of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1992;176:74-6.
44. Staud R, Nagel S, Robinson ME, Price DD. Enhanced central pain processing of fibromyalgia patients is maintained by muscle afferent input: A randomized, double-blind, placebo-controlled study. Pain 2009;145(1-2):96-104.
45. Huygen FJ, Ramdhani N, van Toorenenbergen A, Klein J, Zijlstra FJ. Mast cells are involved in inflammatory reactions during Complex Regional Pain Syndrome type 1. Immunol Lett 2004;91(2-3):147-54.
46. Heijmans-Antonissen C, Wesseldijk F, Munnikes RJ, etal. Multiplex bead array assay for detection of 25 soluble cytokines in blister fluid of patients with complex regional pain syndrome type 1. Mediators Inflamm 2006;2006(1):28398.
47. Dowlati Y, Herrmann N, Swardfager W, etal. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67(5):446-57.
48. Lehto SM, Niskanen L, Herzig KH, etal. Serum chemokine levels in major depressive disorder. Psychoneuroendocrinology 2010;35(2):226-32.
49. Ross RL, Jones KD, Bennett RM, etal. Preliminary evidence of increased pain and elevated cytokines in fibromyalgia patients with defective growth hormone response to exercise. Open Immunol J 2010;3:9-18.